Advancing research together through Open Innovation

Watch our video: Creating scientific progress through collaboration

Collaboration Opportunities

  • Clinical Compound Bank

    Access our patient-ready compounds with evidence of human target coverage and manageable tolerability.


  • Preclinical Toolbox

    Access compounds with optimised pharmacological properties for preclinical research to study pathways and mechanisms of disease biology.


  • Target Innovation

    Have a novel target idea or assay for a drug discovery project? Our diverse High Throughput Screening (HTS) compound library may help you advance or validate your idea.



  • New Molecule Profiling

    Explore the properties and therapeutic potential of your novel compounds by leveraging our cheminformatic and screening technologies.


  • Challenges

    Offer and be rewarded for your innovative ideas and research expertise to help overcome difficult R&D barriers.


  • Suggestions

    Do you have an idea, technology or suggestion outside of these categories? We are still welcoming proposals, so please get in touch.




Leading the Way in Open Innovation


200

clinical and preclinical projects in progress

250,000

compounds available from our screening library

14

R&D Challenges awarded to date



Why collaborate through Open Innovation?


Beyond the usual research partnerships – let's push the boundaries of science together

AstraZeneca has spent decades creating unique enabling tools and technologies of interest to the scientific community of investigators. These include optimised compounds with extensive data packages, high throughput screening libraries and facilities, cheminformatics and other in silico analytics, and drug R&D knowhow, expertise and experience. At the same time, academic, research foundation and biotech investigators have been developing insights, tools, technologies, platforms, resources and facilities that complement those of AstraZeneca. Examples include disease pathophysiology and patient care insights, assay, biomarker and imaging technologies, and specialised facilities.

By bringing all of this together through partnering, we can test hypotheses that may otherwise not be possible. Sharing ideas and enabling scientific innovation to cross boundaries between academia, industry, government and non-profit organisations will help us translate innovative ideas into scientific breakthroughs and potential new medicines more quickly and effectively.


At AstraZeneca, we have great scientists doing truly ground-breaking research. But in order to speed up the delivery of the next generation of medicines, we also need to access the best science outside our labs. We are always looking for new ways of working with academic or industry researchers who share our passion for advancing the science and helping patients with unmet medical needs.

Menelas Pangalos EVP, IMED Biotech unit, AstraZeneca


In 2011, a novel agreement between the Medical Research Council (MRC) and AstraZeneca gave academic researchers across the UK unprecedented access to 22 of our clinical and preclinical compounds.

These compounds had stalled in early testing, often because they didn’t prove effective against the original target. But they may still be useful against other diseases. And because the compounds have already undergone some preliminary development, any new treatments arising from the research could reach patients faster. Fifteen studies are currently underway covering respiratory illness, muscular dystrophies, bone disease and various mental health conditions.

AstraZeneca featured news